Since MMP2 and MMP9 are involved in the continued growth of the tumor and metastasis, coupled with the fact that high expression of both is related to poor patient survival in various types of cancers, an OV that targets these markers could be of high clinical value [41]. The gene discussed is MMP9; the disease is neoplasm.